Live Breaking News & Updates on Gastrointestinal reprogramming

Stay informed with the latest breaking news from Gastrointestinal reprogramming on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Gastrointestinal reprogramming and stay connected to the pulse of your community

ASX Health Stocks: AVITA flies as high as 24pc after providing big, bullish guidance

ASX Health Stocks: AVITA flies as high as 24pc after providing big, bullish guidance
heraldsun.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heraldsun.com.au Daily Mail and Mail on Sunday newspapers.

North-carolina , United-states , David-brookes , Leslie-chong , Anatara-ga , Anatara-lifesciences , Gastrointestinal-reprogramming ,

Anatara Lifesciences Provides Update on GaRP IBS Trial

Anatara Lifesciences Provides Update on GaRP IBS Trial
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

David-brookes , While-the-company , Anatara-lifesciences , Gastrointestinal-reprogramming , Irritable-bowel-syndrome , Data-safety-monitoring-board , Generally-recognised ,

Anatara Lifesciences Limited (ASX:ANR) Annual Report to Shareholders - ABN Newswire (@ABN_Newswire)

2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.

Australia , Melbourne , Victoria , Canada , Adelaide , South-australia , Ridley-corporation , Human-research-ethics-committee , Murdoch-university , Anatara-lifesciences , Anatara-lifesciences-limited

Anatara Lifesciences Ltd (ASX:ANR) Market Update - ABN Newswire (@ABN_Newswire)

Anatara Lifesciences Ltd (ASX:ANR) Market Update

Market UpdateMelbourne, April 7, 2021 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) provides an update on development and commercialisation activities for human health and animal health projects.
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing and with a market differentiating focus on evidence based complementary medicine.
Anatara has ethics approval to commence the human clinical trial in irritable bowel syndrome (IBS) with Anatara's Gastrointestinal ReProgramming (GaRP) complementary medicine. Due to a scheduling delay in manufacturing placebo for this trial as a result of reduced shifts under covid restrictions, the Company now anticipates commencing recruitment for the trial in May. This randomised, double-blind, placebo-controlled trial will be conducted in two stages as a virtual trial, with minimal on-site visits and participants completing most assessments online. Up to 6 sites will be used and approximately 200 participants enrolled. All six sites have been initiated with two sites in Victoria, two sites in Queensland, one site in New South Wales and one site in Western Australia.

Australia , United-states , Melbourne , Victoria , Americans , Anatara-ga , Ridley-corporation , University-of-new-england-poultry-hub-australia , Murdoch-university , Anatara-lifesciences-ltd , Euromonitor-health

IBS and mental health: Antara Lifesciences to trial supplement that targets colon and small intestine delivery

Australia company Anatara Lifesciences is trialling the use of a bromelain-containing supplement in patients suffering from irritable bowel syndrome (IBS).

Australia , Australian , Steve-lydeamore , Entrepreneur-programme , Gastrointestinal-reprogramming , Bristol-stool-form , Innovation-connections-grant , Business , Oceania , Healthy-living , Functional-foods-and-drinks , Supplements

IBS and mental health: Anatara Lifesciences to trial supplement that targets colon and small intestine delivery

IBS and mental health: Anatara Lifesciences to trial supplement that targets colon and small intestine delivery
foodnavigator-asia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foodnavigator-asia.com Daily Mail and Mail on Sunday newspapers.

Australia , Australian , Steve-lydeamore , Entrepreneur-programme , Gastrointestinal-reprogramming , Bristol-stool-form , Innovation-connections-grant , ஆஸ்திரேலியா , ஆஸ்திரேலிய , தொழில்முனைவோர்-ப்ரோக்ராம் , இரைப்பை குடல்-மறுபிரசுரம் , பிரிஸ்டல்-மலம்-வடிவம்

Anatara Lifesciences Ltd (ASX:ANR) R&D Tax Incentive Received - ABN Newswire (@ABN_Newswire)

Anatara Lifesciences Ltd (ASX:ANR) R&D Tax Incentive Received

R&D Tax Incentive ReceivedMelbourne, Feb 3, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme. Anatara, as of today, has $4.38 million in cash plus term deposits including $2.38 million in cash and $2 million in a term deposit.
This refund is from Anatara's 2019-2020 research activities and reflects a period of significant investment in the Company's Gastrointestinal ReProgramming (GaRP) complementary medicine which aims to:
(1) address dysbiosis of the microbiome;

Australia , Melbourne , Victoria , Australian , Steven-lydeamore , Anatara-lifesciences , Australian-taxation-office , Company-gastrointestinal-reprogramming-ga , Anatara-lifesciences-ltd , Government-research , Federal-government , Gastrointestinal-reprogramming